You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
873 ISM5939, a novel, potent, orally available, selective ENPP1 inhibitor enhances the anti-tumor effects of immune checkpoint inhibitors in syngeneic murine cancer models

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023192018
Dec 20234008
Jan 20244904
Feb 2024276020
Mar 20247007
Apr 20244805
May 202448017
Jun 20243603
Jul 202411408
Aug 20243807
Sep 2024104013
Oct 202411207
Nov 2024334028
Dec 2024160020
Jan 2025212018
Feb 202572021
Mar 20250018
Apr 20250013
May 20250010
Jun 2025008
Total19050253